| DIRECT COMPETITOR COMPARISON | |
| ALNY | CYTR | MRK | VRX | Industry | | Market Cap: | 692.87M | 112.12M | 75.95B | 2.63B | 100.26M | | Employees: | 175 | 31 | 55,200 | 2,331 | 68 | | Qtrly Rev Growth (yoy): | -5.80% | 657.90% | 1.80% | 30.80% | 19.70% | | Revenue (ttm): | 98.31M | 10.83M | 23.37B | 772.95M | 14.01M | | Gross Margin (ttm): | -2.31% | 100.00% | 76.36% | 75.52% | 65.67% | | EBITDA (ttm): | -41.20M | -6.20M | 7.81B | 300.35M | -12.30M | | Oper Margins (ttm): | -48.68% | -63.11% | 26.63% | 28.93% | -149.46% | | Net Income (ttm): | -49.19M | -5.87M | 8.05B | -32.02M | N/A | | EPS (ttm): | -1.185 | -0.061 | 3.808 | -0.640 | -0.33 | | P/E (ttm): | N/A | N/A | 9.46 | N/A | 16.37 | | PEG (5 yr expected): | N/A | N/A | 2.18 | 0.92 | 1.31 | | P/S (ttm): | 7.14 | 10.48 | 3.28 | 3.45 | 9.35 |
|
| CYTR = CytRx Corporation | | MRK = Merck & Co. Inc. | | VRX = Valeant Pharmaceuticals International | | Industry = Biotechnology | |
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 56.54 | 0.07% | 57.23B | 12.33 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 47.44 | 1.11% | 13.72B | 15.88 | | Genzyme Corp. | GENZ | 51.27 | 0.39% | 13.61B | 29.23 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.34 | -0.47% | 41.70B | 17.92 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 49.61 | -0.68% | 8.85B | 1012.45 | | Teva Pharmaceutical Industries Limited | TEVA | 52.892 | 0.02% | 46.60B | 48.39 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 37.53 | 1.54% | 3.98B | 19.35 | | Barr Pharmaceuticals, Inc. | Private - View Profile | | King Pharmaceuticals Inc. | KG | 11.96 | 0.08% | 2.97B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 17.85 | -0.89% | 5.45B | 109.51 | | Pfizer Inc. | PFE | 18.29 | 0.22% | 147.59B | 15.19 | | Johnson & Johnson | JNJ | 62.4982 | -0.62% | 172.44B | 13.65 | | GlaxoSmithKline plc | GSK | 41.47 | -1.87% | 105.13B | 13.17 | | Sanofi-Aventis | SNY | 37.88 | -1.43% | 98.91B | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Novartis AG | NVS | 55.59 | 0.38% | 126.26B | 16.64 | | RHHBY.PK | 40.73 | -1.76% | N/A | N/A | | AstraZeneca plc | AZN | 44.71 | -1.28% | 64.83B | 8.98 | | Abbott Laboratories | ABT | 53.725 | -0.66% | 83.10B | 14.56 | | Bristol-Myers Squibb Co. | BMY | 25.29 | -0.35% | 50.10B | 13.08 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | MRK | | China Biotech Week in Review: Two More R&D Centers, One PE Fund, One IPO
Mon 7:33am -
at Seeking Alpha | | • | MRK | | UPDATE - GSK files rotavirus vaccine for approval in Japan
Mon 3:44am -
at Reuters | | • | MRK | | Increase In Patent Protection For Biologics Creates Significant Upside For Drug Development Enterprise Valuations
Sat, Nov 28 -
Wall Street Transcript | | • | MRK | | 3 Stocks Springing Back
Fri, Nov 27 -
at Motley Fool | | • | MRK | | 3 China Profit Plays
Fri, Nov 27 -
at Motley Fool | | • | MRK | | INSIDE WASHINGTON: Stream of WH health care visits
Thu, Nov 26 -
AP | | • | CYTR | | CytRx Announces First of Two Positive Developments Ahead
Thu, Nov 26 -
at Seeking Alpha | | • | CYTR | | CytRx Announces Plan to Initiate a Phase 2 Clinical Trial with INNO-206 in Patients with Advanced Soft Tissue Sarcomas
Tue, Nov 24 -
Business Wire | | • | CYTR | | CytRx Corporation: Key Developments Ahead
Tue, Nov 24 -
at Seeking Alpha | | • | VRX | | Valeant Pharma begins selling generic IBS drug
Mon, Nov 23 -
AP | | • | VRX | | [$$] Valeant Shares Fall Ill
Mon, Nov 23 -
at Barrons.com | | • | CYTR | | Pending Key Developments Ahead for CytRx Corporation (NASDAQ: CYTR)
Mon, Nov 23 -
Marketwire | | • | CYTR | | CytRx: Technical Breakout Imminent
Mon, Nov 23 -
at Seeking Alpha | | • | VRX | | Barron's Magazine First Read: Dividends, VRX, DISCA
Mon, Nov 23 -
at Barrons.com | | • | VRX | | Oceanside Pharmaceuticals Announces Launch of Librax(R) AG
Mon, Nov 23 -
PR Newswire | | • | VRX | | Valeant may fall if new drug disappoints-Barron's
Sun, Nov 22 -
at Reuters | | • | VRX | | [$$] Hot Drug Stock in Need of a Chill Pill
Sat, Nov 21 -
at Barrons.com | | • | CYTR | | CytRx to Initiate Phase 2 Clinical Trial with INNO-206 in Patients with Advanced Gastric Cancer
Wed, Nov 18 -
Business Wire | | • | CYTR | | CYTRX CORP Financials
Fri, Nov 13 -
EDGAR Online Financials | | • | CYTR | | CYTRX CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
Mon, Nov 9 -
EDGAR Online | | | All Headlines for these symbols... |
|
|
|
0.31% Nasdaq 
0.21 (1.25%) 
Competitors
